Merck & Co.
AWARDS
NEWS
Merck entered into collaborations with three different companies as it continues to assess Keytruda in combination with experimental drugs in different cancer indications.
The two Phase III studies are part of the ILLUMINATE clinical trial, which looks into the action of doravirine/islatravir (DOR/ISL) on HIV-1.
Novartis announced the CANOPY-1 Phase III trial of canakinumab failed to meet its primary endpoints when combined with Merck’s checkpoint inhibitor Keytruda (pembrolizumab).
Lexington, Mass.-based Agenus withdrew its Biologics License Application for balstilimab from the U.S. FDA. The drug is a PD-1 inhibitor or checkpoint inhibitor.
The designation is based on data from two Phase I trials, which showed the drug to be safe, demonstrating early efficacy.
The entire lot of CUBICIN (daptomycin), numbered 934778, which has an expiry date of June 2022, will be recalled from the user level, including administering institutions and hospitals.
JOBS
IN THE PRESS